INNATE PHARMA SA-SPONS ADR (IPHA)

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Innate Pharma to Host Virtual KOL Event on Lacutamab

Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update

Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update

Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023

Innate Pharma Announces Its Participation to Upcoming Investor Conferences

Innate Pharma 2024 Financial Calendar

Innate Pharma Announces Abstracts Selected for ESMO Congress 2023

Number of Shares and Voting Rights of Innate Pharma as of October 3, 2023

Innate Pharma stock slips on FDA clinical hold (NASDAQ:IPHA)

Innate Pharma stock drops as FDA imposes partial clinical hold on two trials for lymphoma candidate lacutamab, after a fatal rare blood disorder. Read more here.

Innate Pharma Provides Update on Lacutamab Clinical Program

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

Innate Pharma Reports First Half 2023 Financial Results and Business Update

Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update

Innate Pharma to Participate in Upcoming Investor Conference

First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023

First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer

Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria

Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma

Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress

Why Shares of Innate Pharma Jumped Thursday

The company's collaboration agreement with Sanofi could soon pay off.

SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML

Innate Pharma to Participate in Upcoming Investor Conferences

Outcome of Innate Pharma’s 2023 Annual General Meeting

Innate Pharma Reports First Quarter 2023 Financial Results and Business Update

Number of shares and voting rights of Innate Pharma as of May 1, 2023

Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting

Innate Pharma Announces Conference Call and Webcast for Q1 Business Update

Innate Pharma Establishes a New At-The-Market (“ATM”) Program on Nasdaq

Innate Pharma to Participate in Upcoming Investor Conference

Number of Shares and Voting Rights of Innate Pharma as of April 1, 2023

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 12, 2023

Innate Pharma Files Its 2022 Universal Registration Document (Document d’enregistrement universel) and 2022 Annual Report on Form 20-F

Innate stock surges after license deal with Takeda (IPHA)

Innate Pharma (IPHA) stock rose ~15% after the company said it signed a license agreement with Takeda. Read more here